BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26561496)

  • 1. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
    Antivir Ther; 2016; 21(4):353-8. PubMed ID: 26561496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
    HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
    Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
    Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
    J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
    Brogan AJ; Davis AE; Goodwin B
    PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
    Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
    Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
    Jose S; Nelson M; Phillips A; Chadwick D; Trevelion R; Jones R; Williams DI; Hamzah L; Sabin CA; Post FA;
    AIDS; 2017 Feb; 31(4):485-492. PubMed ID: 28121667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
    Dentone C; Di Biagio A; Cozzi Lepri A; Fenoglio D; Filaci G; Lichtner M; Carrara S; Giacometti A; Sighinolfi L; Marchetti G; Antinori A; D'arminio Monforte A;
    HIV Clin Trials; 2018 Aug; 19(4):158-162. PubMed ID: 30422095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
    Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
    Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
    Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
    HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord
    Eur J Clin Pharmacol; 2017 Apr; 73(4):463-468. PubMed ID: 28028587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher plasma drug levels in elderly people living with HIV treated with darunavir.
    Tyrberg E; Edén A; Eriksen J; Nilsson S; Treutiger CJ; Thalme A; Mellgren Å; Gisslén M; Andersson LM
    PLoS One; 2021; 16(2):e0246171. PubMed ID: 33539440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
    Strehlau R; Donati AP; Arce PM; Lissens J; Yang R; Biguenet S; Cambilargiu D; Hardy H; Correll T
    J Int AIDS Soc; 2015; 18(1):19467. PubMed ID: 26066346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
    Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
    HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
    d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
    HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.